Data Insights

Filter search results

By Company Name
By Disease Name
By Drug Name
By Themes
Showing 20 results out of 48682
Features

Pharma Technology Focus - Issue 20

Logistics and Supply Chain Issue: In this issue we explore logistical problems faced by distributors moving sensitive drugs across the Africa, investigate the latest IT tools revolutionising the supply chain for pharmaceuticals and also find out how legislation changes could reverse drug shortages.

Features

Virtualising the pharma chain – why the cloud is the only way forward

As pharmaceutical supply networks become more and more complex, involving collaboration between hundreds, or even thousands, of entities around the world, traditional supply chain management tools are struggling to keep up. Elly Earls met GT Nexus's Greg Kefer and TraceLink's Shabbir Dahod to find out why moving to the cloud is the only way forward.

Features

Pharmaceutical science - catching up with Armstrong’s doping Peloton

The exposure of Lance Armstrong's doping campaign has rocked not only the world of cycling, but also anyone who had any faith in anti-doping pharmacology and detection. Liam Stoker investigates Armstrong's meticulous use of performance-enhancing drugs, and how pharmaceutical science has finally begun to catch up.

Features

September's top stories: Roche's injectable Herceptin endorsed by EU

Roche has won EU approval for a new injectable formula of its breast cancer drug, Herceptin, while Bayer HealthCare has obtained two separate orphan drug designations from the FDA's Office of Orphan Products Development, for its investigational oral drug riociguat. Pharmaceutical-technology.com wraps up key headlines from September 2013.

Features

Treating type 2 diabetes – a 21st century pandemic

With the number of people diagnosed with type 2 diabetes set to double in the next ten years Dr Valentina Gburcik, GlobalData's analyst in cardiovascular and metabolic disorders, looks at what this will mean for the pharmaceutical industry.

Features

Testing painkillers on humans – why hold back?

Deliberately inflicting carefully controlled painful stimuli on human volunteers could reduce costs and speed up development of new painkilling drugs, according to a new study by Dr Jörn Lötsch of Goethe-University Frankfurt. Elly Earls met the veteran pain researcher to find out if the future of analgesic drug development really is set to be a case of no pain, no gain.

Features

People power: crowdfunding clinical research

With research funding being slashed across the board, could crowdfunding provide the extra cash needed to develop innovative new treatments? Chris Lo discusses people power with the minds behind CureLauncher, a new clinical research crowdfunding platform in the US.

Genting invests $111.8m in TauRx Pharmaceuticals

Genting Management, a subsidiary of Genting Berhad, has invested $31.5m in Singapore-based TauRx Pharmaceuticals, as the first tranche of a $111.8m investment in the pharmaceutical company in return for a 20% equity stake.

Features

Healthcare's black hole: preventing pharmaceutical cargo theft

Cargo theft in the healthcare industry has increased across the globe, and even where actual incidence rates have dropped, the value of stolen items has increased significantly. Dr Nicola Davies reports on a dangerous trend and finds out how security can be improved as drugs make their way from the manufacturing facility to the shelves.

Features

Tackling pharmaceutical counterfeits: beyond packaging

With a large proportion of the developing world unable to afford genuine medication, black market counterfeits are the only option for many. As a result, a shocking number of medicines on the market are fakes. Dr Nicola J Davies finds out more about the risk to patients and the huge profit loss incurred by the pharmaceutical industry.

Features

Virus-Like Particles: Vaccines of Tomorrow?

Virus-like particles represent one of the most exciting new technologies to rapidly produce vaccines. Elisabeth Fischer speaks to industry experts to find out about this cheaper and quicker way to generate effective vaccines with long-lasting protection.

Features

Snapshot: Coronary Artery Disease Global Clinical Trials 2011

An estimated 17 million people die of coronary artery disease worldwide every year, and numbers are rising. While pharmaceutical efforts to find a cure have always been fiercely competitive, few contenders have emerged to challenge time-tested drugs and their generics. But, as this special report snapshot shows, a host of new trials and targeted therapeutics are beginning to show serious dividends.

Features

Combating the Counterfeit Culture

The global counterfeit medicines market is threatening public health and the reputation of the legitimate pharmaceutical industry. Chris Lo finds out the extent of the problem and how the industry and health organisations are responding.